Vimarsana
Biggest News Aggregation in the World

Alipss News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alipss. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alipss Today - Breaking & Trending Today

Umhlali stumps up R100k to replace KZN search and rescue dog Dante - Vimarsana News

Umhlali stumps up R100k to replace KZN search and rescue dog Dante

A crowdfunding initiative has raised R100,000 to pay for the successor of one of the most valuable members of KwaZulu-Natal’s Umhlali search and rescue team, police dog Dante.

Updates to MDS Classification Complicate Yet Better Inform Treatment Navigation in MDS - Vimarsana News

Updates to MDS Classification Complicate Yet Better Inform Treatment Navigation in MDS

Mikkael A. Sekeres, MD, MS, discusses the influence of therapeutic developments and conflicting classification systems on the management of MDS.

Search continues for missing man in Umvoti River - Vimarsana News

Search continues for missing man in Umvoti River

Search and Rescue officials will return to the uMvoti river, on the north coast, on Saturday in search of a man who went missing during a cleansing ceremony this week.

Source: ecr.co.za
KZN floods claim more victims - Vimarsana News

KZN floods claim more victims

Three bodies were discovered in a car on the N11 in the flood-hit town of Ladysmith in KwaZulu-Natal on Saturday. In a separate incident, a person from Ezakheni was reported to have drowned.

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study - Vimarsana News

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study

Amer Zeidan, MBBS, MHS, presents data from the IMerge phase 3 study on the efficacy of imetelstat in achieving red blood cell transfusion independence across different risk subgroups in patients with lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis-stimulating agents.